Skip to main content

Table 1 Patient characteristics

From: Prognostic effect of matrix metalloproteinase-9 in patients with resected Non small cell lung cancer

  Tumor MMP-9 P
No ExpressionN(%) ExpressionN(%)
Age    0.820
  Below median 137 (53.5) 88 (54.7)  
  Above median 119 (46.5) 73 (45.3)  
Sex    0.099
  Male 179 (69.9) 100 (62.1)  
  Female 77 (30.1) 61 (37.9)  
Histology    0.001
  Squamous cell 130 (50.8) 45 (28.0)  
  Adenocarcinoma 103 (40.2) 99 (61.5)  
  Large cell 11 (4.3) 9 (5.5)  
  Others 12 (4.7) 8 (5.0)  
Stage    0.001
  I 158 (61.7) 77 (47.8)  
  II 70 (27.4) 51 (31.7)  
  IIIA 28 (10.9) 33 (20.5)  
T stage    0.068
  T1 75 (29.3) 33 (20.5)  
  T2 147 (57.4) 105 (65.2)  
  T3 32 (12.5) 18 (11.2)  
  T4 2 (0.8) 5 (3.1)  
N stage    0.002
  N0 204 (79.7) 108 (67.1)  
  N1 35 (13.7) 30 (18.6)  
  N2 17 (6.6) 23 (14.3)  
Lymphovascular invasion    0.549
  No 224 (87.5) 144 (89.4)  
  Yes 32 (12.5) 17 (10.6)  
Postoperative Treatment    0.000
  Chemotherapy 73 (28.5) 71 (44.1)  
  Radiation therapy 7 (2.7) 2 (1.2)  
  Combination therapy 19 (7.4) 20 (12.4)  
  No treatment 157 (61.3) 68 (42.2)  
  1. MMP-9: matrix metalloproteinase-9; Combination therapy: Chemotherapy + Radiation therapy.